Multiple disease processes are associated with cognitive impairment in Parkinson disease (PD), including Lewy bodies, cerebrovascular disease, and Alzheimer disease. It remains unknown whether tau pathology relates to cognition in patients with PD without dementia.
M ild cognitive impairment is estimated to affect approximately 25% to 30% of patients with Parkinson disease (PD). 1 Postmortem studies suggest that cognitive decline in PD is related to the combined influence of α-synuclein (a protein associated with presynaptic terminal function and the regulation of dopamine), the development of Alzheimer disease (AD), and cerebrovascular factors. 2, 3 Work in animal and cellular models has demonstrated that a synergistic relationship between α-synuclein and AD might accelerate cognitive decline. [4] [5] [6] [7] Despite this evidence for the contribution of multiple disease processes to cognitive impairment in PD, recent studies using positron emission tomographic (PET) imaging to measure AD biomarkers in patients with PD have reported mixed findings. [8] [9] [10] Studies of deposits of tau protein, the dysfunction of which is implicated in dementia, have used PET imaging and the tracer fluorine 18-labeled AV-1451 ([ 18 F]AV-1451) to show elevated binding in patients with dementia with Lewy bodies and Parkinson disease dementia relative to healthy controls. 8, 9 The relationship between cortical tau aggregation and cognitive dysfunction seen in AD has also been observed in Lewy body diseases. [11] [12] [13] However, patients with PD who had mild cognitive impairment (PD-MCI) showed no differences in tau PET scan results compared with patients with PD who were cognitively normal (PD-CN). 10 Crucially, this study 10 left unresolved whether β-amyloid (Aβ) plaques are associated with tau in the brains of people with PD, and whether the 2 disease processes might jointly contribute to cognitive impairment in PD. Positron emission tomography measures of cortical Aβ in patients with PD who do not have dementia have demonstrated an association between longitudinal cognitive decline and cortical Aβ burden despite a lack of relationships between Aβ and baseline cognition. 14 We investigated the contributions of AD processes to cognitive impairment in PD by collecting both tau and Aβ PET scan data from 14 mildly cognitively impaired and 15 cognitively normal patients with PD, as well as 49 healthy control participants. In examining the contributions of both tau and Aβ to cognitive status in patients with PD who do not have dementia, we hypothesized that tau aggregation across both groups would be related to age and Aβ status.
Methods

Participants
We recruited 30 patients with PD through the University of California, San Francisco Memory and Aging Center, including 15 with mild cognitive impairment (PD-MCI) and 15 cognitively normal individuals with PD (PD-CN).
All patients with PD met the clinical diagnostic criteria of the UK Parkinson's Disease Society Brain Bank. 15 In addition, this participant group underwent neuropsychological assessments, including the Montreal Cognitive Assessment and additional assessments spanning 5 cognitive domains known to be sensitive to idiopathic PD: attention and working memory, executive function, language, episodic memory, and visuospatial function. Patients with PD met criteria for mild cognitive impairment by demonstrating level 2 clinical categorization via comprehensive assessment and by self-reported or informant-reported cognitive decline on interview, as described by Litvan et al 16 ; in other words, patients were characterized as having PD-MCI if they performed 1 to 2 SDs below age-matched and sex-matched norms on 2 or more neuropsychological tests. Patients underwent medical history and neurological examination by a qualified neurologist. Severity of motor symptoms was measured using the Unified Parkinson's Disease Rating Scale version 3. 17 All patients were diagnosed by clinicians who were blinded to PET imaging at a consensus case conference. Additionally, 49 cognitively normal control participants were recruited from the Berkeley Aging Cohort Study, an ongoing longitudinal study of cognitive aging. Control participants underwent cognitive assessment via the Mini-Mental State Examination 18 and were included in the study if they scored 25 or more, indicating normal cognitive function. In addition to detailed neuropsychological assessment, all study participants underwent structural magnetic resonance imaging (MRI) and [ imaging. Control participants were included in the study based on their Aβ status, which was determined by PET scan. In addition, 3 control participants 60 years or younger did not receive these scans but were included in the Aβ-negative analysis group because cognitively healthy individuals are unlikely to have cortical Aβ pathology before age 60 years. 19 For this study, exclusion criteria of people with PD and control participants included the presence of a non-PD neurological disorder, major systemic illness, contraindications to MRI or PET, or history of a substance use disorder. In addition, 1 person with PD-MCI did not receive a magnetic resonance imaging (MRI) scan and thus was excluded from all analyses. Therefore 29 patients with PD were included in this study along with 49 control participants.
The study was approved by institutional review boards at all participating institutions. Written informed consent was obtained from all participants.
Key Points
Question How are tau, β-amyloid, and cognitive status associated in Parkinson disease?
Findings This cross-sectional positron emission tomographic imaging study examined β-amyloid and tau deposition in 15 cognitively normal patients with Parkinson disease, 14 cognitively impaired patients with Parkinson disease, and 49 cognitively normal older control participants. Tau deposition was not related to cognitive status in patients with Parkinson disease, but was significantly associated with age and β-amyloid regardless of diagnostic category.
Meaning
The presence of tau and β-amyloid in patients with Parkinson disease does not explain their cognitive functioning, although increased tau accumulation is seen in individuals with greater levels of brain β-amyloid.
Magnetic Resonance Imaging
The research team acquired 1 × 1 × 1-mm-resolution T1-weighted magnetization prepared rapid gradient echo images for every participant on a 1.5-T MRI scanner at Lawrence Berkeley National Laboratory (using techniques described previously 13 ). These scans were processed with FreeSurfer version 5.3.0 (Massachusetts General Hospital) (http://surfer.nmr .mgh.harvard.edu/) to derive regions of interest (ROIs) in the native space of each participant using the Desikan-Killiany atlas, a feature of FreeSurfer software. FreeSurfer ROIs were used to calculate regional tau PET measures in the native space of each participant (after partial volume correction).
Magnetic resonance images were also segmented into tissue types using Statistical Parametric Mapping software, also known as SPM12 (Wellcome Trust Centre for Neuroimaging). The segments derived from SPM12 for noncerebral tissues were subsequently used for partial volume correction. Segments for gray and white matter were warped to Montreal Neurological Institute (MNI) 152 T1-weighted template at 2-mm isotropic resolution, and these were used to warp tau PET images into MNI space.
PET Imaging
A detailed description of the acquisition process for [ 11 
PET Imaging for Measurement of Tau
To measure tau protein, we created [
18 F]AV-1451 standardized uptake volume ratio (SUVR) images based on the mean uptake over 80 to 100 minutes postinjection, 24 normalized by the mean inferior cerebellar gray matter uptake. The SUVR images were coregistered and resliced into structural magnetic resonance images. To account for partial volume effects due to atrophy and signal spillover, we used the Geometric Transfer Matrix approach 25 for partial volume correction based on
FreeSurfer-derived ROIs, including corrections for extracerebral tissue as previously described. 13, 21 Voxelwise analyses used SUVR images (without partial volume correction) that were transformed into MNI-152 space and were smoothed prior to analysis using an 8-millimeter isotropic, full-width at halfmaximum gaussian kernel. We quantified [
18 F]AV-1451 uptake by grouping together ROIs that corresponded to the pathologic stages of tau protein tangle deposition in AD described by Braak and Braak. 26 The regions grouped in each Braak stage ROI have been published previously. 21 Specifically, we calculated weighted mean SUVR in native space (after partial volume correction) from 3 composite ROIs that roughly correspond to anatomical definitions of AD Braak stages 0 (an informal stage included for the purpose of this study in which no AD lesions are observed by PET scan), stage 1/2 (which show tau-related disease processes in the transentorhinal portion of the brain), stage 3/4 (which expands in which tau pathology is present to encompass the limbic system), and stage 5/6 (which displays the same processes in neocortical regions). Participants were then categorized into AD Braak stages according to thresholds that were based on Braak ROI-specific tracer uptake in different clinical groups, which were previously derived using conditional inference regression tree analysis. 21 Participants with a mean SUVR of more than 1.129 met the classification for stage 1/2; those with a mean SUVR of more than 1.304 were judged to be at stage 3/4, and those whose mean SUVR was more than 1.873 were categorized as stage 5/6. 21 Participants were classified at the highest stage for which they exceeded the cutoff. Additionally, we compared the mean SUVRs of FreeSurferderived bilateral inferior temporal lobe and precuneus ROIs to investigate [ 18 F]AV-1451 uptake differences, which have previously been reported in patients with severe PD and dementia with Lewy bodies. 8 We also looked at [
18 F]AV-1451 uptake in a FreeSurfer-derived bilateral putamen ROI. The putamen has been reported as a site of high [ 18 F]AV-1451 uptake, which is presumed to be off target 13, 27 ; however, the pattern of uptake in putamen has been found to demonstrate elevation in people with other movement disorders, such as corticobasal degeneration. 28 ]PiB PET scan. Differences between groups in native-space Braak-stage ROIs and MNI-space substantia nigra ROIs were assessed using nonparametric Kruskal-Wallis tests, followed by post hoc Mann-Whitney U groupwise comparisons. Nonparametric tests were applied because of small group sizes and because they do not require the data to be normally distributed. Age and education associations were examined with Pearson correlation coefficients.
Statistical Analysis
Results
Participant characteristics are summarized in the Table) . Impairment was defined as performance at or below 1 SD from age-matched and sex-matched norms on 2 or more neuropsychological tests. 16 Of 14 patients with PD-MCI, 2 were impaired in a single cognitive domain (14%), 9 were impaired in 2 domains (64%), and 3 were impaired in 3 domains (21%). The distribution of impaired cognitive domains is illustrated in Figure 1 . The 2 most common impairments were in attention and working memory and in episodic memory.
β-Amyloid Burden
Of the 29 patients with PD, 6 (21%) were Aβ-positive (Table) . One Aβ-positive patient met criteria for PD-MCI, and 5 were cognitively normal. Of the Aβ-negative patients with PD, 13 met criteria for PD-MCI and 10 were cognitively normal. Patients with PD-MCI were characterized as performing at 1 to 2 SD below published age-matched and sex-matched norms on 2 or more neuropsychological tests. The bar plot shows the number of patients with PD-MCI who were impaired in each cognitive domain; 2 patients were impaired in a single domain, 9 across 2 domains, and 3 across 3 domains. with PD who were Aβ-positive was not significantly different from that of Aβ-positive control participants, while binding in patients with PD who were Aβ-negative was not significantly different from that of Aβ-negative control participants at any all AD Braak-stage ROI.
Research Original Investigation
Tau, Amyloid, and Age Across patients with PD and control participants, the mean (Figure 4) . Tracer binding in the bilateral putamen, believed to reflect off-target tracer binding, 12,13,33 also correlated with age ( Figure 4 ; r = 0.52, P < .001).
Discussion
To our knowledge, this is the first study to use PET scans to examine Aβ and tau in relationship to cognitive status in patients with PD but not dementia, and the first finding that tau binding observed via PET scan is related to Aβ status in patients with PD without dementia. We found that patterns of tau and Aβ did not differ between patients with PD-MCI and those with PD-CN, and that the binding of tau PET tracer in patients with PD did not differ from Aβ-negative healthy controls. Furthermore, Aβ status in patients with PD was not related to cognitive status, and the proportion of patients with PD in this study who were Aβ-positive (21%) was comparable with healthy controls of the same age range. 34 Additionally, we found that tau observable via PET scan had similar associations with age and Aβ status in patients with PD as in healthy control participants. This study replicates a report that patients with PD-MCI and patients with PD who were cognitively normal do not show significant differences in levels of brain tau. 10 Previous work with tau observed via PET scan has shown elevated tracer binding in the brains of patients with PD-MCI relative to healthy controls, specifically in the precuneus and inferior temporal gyrus. 8 We did not find elevated tau in these brain regions in the present cohort of patients with PD-MCI. It is likely that the contrast in tau between cognitively impaired and patients with PD who were cognitively normal (as reported in Gomperts et al 8 ) was driven by increases observed in patients with PD who had dementia, who were not included in this study. Cognitive status was not related to Aβ status in the present cohort of patients with PD, which was unsurprising given the previous finding that, while [ 11 C]PiB-indexed Aβ burden may contribute to longitudinal cognitive decline, it does not distinguish between patients with PD-MCI and patients with PD who were cognitively normal at baseline. 14 Our analyses also tients with PD relative to a control group. This contrast has been suggested to reflect off-target tracer binding to neuromelanincontaining dopaminergic neurons in the substantia nigra; progressive loss of nigral neurons may be related to disease progression in PD. 29 In this study, we did not find an association between [
18 F]AV-1451 binding in the substantia nigra and motor impairment or global cognition.
While α-synuclein pathology is considered the hallmark feature of PD, post-mortem studies of people with PD-MCI suggest that the pathological processes of AD and cerebrovascular factors additionally contribute to cognitive decline. 2, 3 The onset and severity of dementia in Lewy body diseases is also associated with pathologies beyond changes in α-synuclein, 35, 36 and work in animal and cellular models has suggested a synergistic relationship between changes in α-synuclein and AD processes that accelerates cognitive decline. [4] [5] [6] Providing further evidence for these multipathology interactions are postmortem findings that pathological tau colocalizes to α-synuclein in Lewy bodies, particularly in brain regions known to be vulnerable to both Lewy bodies and neurofibrillary tangle disease processes. 7 Current tools do not allow us to measure the distribution of unhealthy α-synuclein protein in the bodies of living patients. However, our findings suggest that any presence of α-synuclein in the patients with PD included in this study has not influenced the spread of tau protein, as detectable by [ 18 F]AV-1451 PET scan. While this result may be surprising given the postmortem and animal evidence supporting synergy and colocalization of α-synuclein and tau, [4] [5] [6] [7] it may be that these relationships are not detectable until patients express symptoms of dementia. 8 Abnormal developments of tau and Aβ did not explain cognitive status in this cohort of patients with PD. While abnormalities in α-synuclein and a decline in dopaminergic functioning are thought to be the main contributors to disease severity in PD, [37] [38] [39] 46 The lack of a relationship between cognitive impairment and AD-related PET biomarkers in PD highlights the need for an α-synuclein ligand for PET scanning, which would be a crucial tool for understanding the interaction between pathology and symptoms in PD. Importantly, mood and lifestyle factors may additionally contribute to cognitive status, as suggested by reports of increased depressive symptoms in cognitively impaired patients 43 as well as evidence that sleep may mediate cognitive symptoms of PD. 47, 48 Thus, health care professionals and/or family caregivers may wish to address mood and lifestyle factors in cognitively impaired patients, and further research should determine whether lifestyle factor interventions can improve cognitive function in these patients.
Limitations
Limitations of the present study include a small sample size. A sample that included more patients with PD-MCI would allow for contrasts between different domains of cognitive impairment. The nonspecificity of cognitive impairment as defined by current PD-MCI criteria 16 may explain the lack of uniform patterns of AD across patients. It is also important to note that [
18 F]AV-1451 does not bind to all forms of pathological tau protein, but preferentially binds to paired-helical filament tau, allowing for the possibility that other forms of abnormal tau accumulation are not measured by this tracer 49 and therefore not represented in this study. 
